Browse
Submit Data
Databases
API
Help

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy.

ABSTRACT: CD1d-restricted invariant natural killer T cells (iNKT) constitute an important immunoregulatory T-cell subset involved in the induction of antitumor immune responses. Here, we provide a view on the recent observation that Vγ9Vδ2-T cells, through trogocytosis of CD1d-containing membrane fragments, have the capacity to act as antigen presenting cells for iNKT.

SUBMITTER: Werter IM

PROVIDER: S-EPMC4292710 | biostudies-other | 2014 Oct

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Project description: Not available

| S-EPMC3869003 | biostudies-literature

Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy.

Project description: Not available

| S-EPMC7994724 | biostudies-literature

Nanoscale artificial antigen presenting cells for T cell immunotherapy.

Project description: Not available

| S-EPMC4114774 | biostudies-literature

Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.

Project description: Not available

| S-EPMC4154451 | biostudies-literature

Size-transformable antigen-presenting cell-mimicking nanovesicles potentiate effective cancer immunotherapy.

Project description: Not available

| S-EPMC7732193 | biostudies-literature

Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy.

Project description: Not available

| S-EPMC4993816 | biostudies-other

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.

Project description: Not available

| S-EPMC5840134 | biostudies-literature

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [human]

Project description:Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAAs) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid lineage reprogramming to directly convert cancer cells into tumor reprogrammed-APCs (TR-APCs). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology.

2022-12-31 | GSE216559 | GEO

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy [mouse]

2022-12-31 | GSE216229 | GEO

The actin cytoskeleton modulates the activation of iNKT cells by segregating CD1d nanoclusters on antigen-presenting cells.

Project description: Not available

| S-EPMC4760795 | biostudies-literature